Table 4 Recurrence, its treatment and survival in the whole cohort and the five most frequent tumor entities (initially curatively treated patients only)
From: Sinonasal malignancies: histopathological entities, regional involvement and long-term outcome
Whole cohort | Squamous cell carcinoma | Adeno-carcinoma | Melanoma | Adenoid cystic carcinoma | Esthesio-neuroblastoma | |
|---|---|---|---|---|---|---|
Total patients | 130 (100) | 69 (100) | 21 (100) | 16 (100) | 9 (100) | 7 (100) |
Recurrence/persistence* | 56 (43.1) | 23 (33.3) | 12 (57.1) | 9 (56.3) | 5 (55.6) | 3 (42.9) |
Localization | ||||||
Local | 26 (20) | 9 (13) | 8 (38.1) | 4 (25) | 2 (22.2) | 2 (28.6) |
Loco-regional | 7 (5.4) | 5 (7.2) | 1 (4.8) | 1 (6.3) | 0 | 0 |
Regional | 9 (6.9) | 7 (10.1) | 1 (4.8) | 0 | 0 | 1 (14.3) |
Loco-regional and distant | 7 (5.4) | 1 (1.4) | 1 (4.8) | 2 (12.5) | 1 (11.1) | 0 |
Distant only | 7 (5.4) | 1 (1.4) | 1 (4.8) | 2 (12.5) | 2 (33.3) | 0 |
Months to recurrence/persistence* or death; median (range) | 10 (1°–73) | 6 (1°–20) | 11 (3–73) | 14 (3–73) | 14 (2°–33) | 36 (20–71) |
Neck level of regional recurrence (rcN) | I: 4 II: 7 Multiple: 2 | I: 4 II: 5 | II: 1 Multiple: 1 | II: 1 | 0 | Multiple: 1 |
Treatment | ||||||
Salvage Sx | 15 (11.5) | 7 (10.1) | 4 (19) | 2 (12.5) | 1 (11.1) | 1 (14.3) |
Salvage Sx + RT | 16 (12.3) | 8 (11.6) | 3 (14.2) | 3 (18.8) | 1 (11.1) | 0 |
Salvage ND | 13 (10) | 10 (14.5) | 0 | 1 (6.3) | 0 | 0 |
Salvage RT | 2 (1.5) | 0 | 1 (4.8) | 1 (6.3) | 0 | 0 |
Palliation | 16 (12.3) | 7 (10.1) | 2 (9.6) | 4 (25) | 1 (11.1) | 1 (14.3) |
Best supportive care | 3 (2.3) | 1 (1.4) | 1 (4.8) | 0 | 0 | 1 (14.3) |
2nd recurrence | 13 (10) | 4 (5.8) | 5 (23.8) | 2 (12.5) | 1 (11.1) | 1 (14.3) |
Months to death; median (range) | 39 (1–160) | 45 (1–147) | 56 (2–128) | 21 (3–160) | 57 (6–150) | 47 (7–112) |